JAMA Network
About The Study: The data from this study support the potential benefit of oral semaglutide in reducing heart failure events in people with type 2 diabetes and heart failure.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
